The most recent outbreak of corona virus disease 2019 (currently known as COVID-19), which can cause severe respiratory disease in humans, has been a potential threat to human health attracting worldwide attention after the 2003 severe acute respiratory syndrome (SARS) pandemic (WHO, 2004), fol...
After a search of its Adverse Event Reporting System (FAERS) database and the medical literature, FDA identified 33 cases of severe joint pain associated with the use of DPP-4 inhibitors, the agency said in its Drug Safety Communication. Ten of these patients required hospitalization due to dis...
Common (1% to 10%): Immune-mediated pneumonitis, respiratory failure, pulmonary embolism, pleural effusion, oropharyngeal pain, COVID-19 Frequency not reported: Interstitial lung disease, immune-mediated lung disease, acute respiratory failureUpper...
Allocetra is a universal off-the-shelf cell therapy that reprograms diseased macrophages in patients with sepsis, COVID-19, and solid tumors to their homeostatic state (Fig.4; Table1). It has shown promising efficacy in a Phase II investigator-initiated clinical trial against severe and critical...
36. Molden E, Andersson KS (2007) "Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients." Pharmacotherapy, 27, p. 603-7 37. Mauro VF, MacDonald JL (1991) "Simvastatin: a review of its pharmacology and clinical use." DICP, 25, p. 257-64 38...
COVID-19SARS-CoV-2PSORIATIC arthritisDear Editor, We conducted a prospective study on adult psoriatic patients referring to the Outpatient Service of Severe Psoriasis after the end of the lockdown due to COVID-19 emergency in Italy (https://www. gazzettaufficiale.it/eli/gu/2020/04/27/108/...
Thus, the final cohort available for outcome analysis comprised 576 participants in the REMAP-CAP severe COVID-19 cohort (whose data are used for covariate adjustment in the primary analysis), of whom 379 were randomized within the corticosteroid domain (after removing 5 patients in the shock-...
Thrombocytopenia has been reported more frequently in patients with moderate or severe forms of COVID-19 infection. It usually occurs more than 10 days after the onset of symptoms [12]. Thus, thrombocytopenia may be a potential biomarker of negative prognosis in patients with COVID-19 [11]. ...
Benis, A.; Banker, M.; Pinkasovich, D.; Kirin, M.; Yoshai, B.E.; Benchoam-Ravid, R.; Ashkenazi, S.; Seidmann, A. Reasons for Utilizing Telemedicine during and after the COVID-19 Pandemic: An Internet-Based International Study.J. Clin. Med.2021,10, 5519. [Google Scholar] [...
Usually, the symptoms of COVID-19 appear after an incubation period of 2–14 days, with an average period of 5.2 days [26]. Most commonly, the onset of COVID-19 is marked by fever, dry cough, fatigue and muscle pain, with other symptoms such as headache, lymphopenia and dyspnoea. Som...